Annals of Hepatology · 2017 · 15 citations · 41 references
MedicineOncologyCancer EpidemiologyGastrointestinal OncologyHepatologyChronic Liver DiseaseCirrhosisHepatocellular CarcinomaLiver CancerLiver DiseaseViral HepatitisHepatic MalignancyHepatic TumorsHepatocellular Carcinoma TreatmentKaplan-meier Confidence IntervalsLiver Cancer EpidemiologyLiver Cancer PrevalenceMortality RatesOverall Mortality
Background. Hepatocellular carcinoma (HCC) is the most common malignancy that develops in cirrhotic livers. Its clinical and epi-demiological characteristics and mortality rates vary according to geographical region. The objective of this study was to evaluate the clinical profile, epidemiological characteristics, laboratory parameters, treatment and survival of patients with HCC. Material and methods. Patients with HCC seen between 2000 and 2012 were studied. The Kaplan-Meier method was used for survival analysis according to variables in question. Results. The study included 247 patients with a mean age of 60 ± 10 years. There was a predominance of males (74%). The main etiologies of HCC were HCV infection (55%), excessive alcohol consumption (12%), and HBV infection (8%). Liver cirrhosis was present in 92% of cases. The mean tumor number and diameter were 2 and 5 cm, respectively. Patients meeting the Milan criteria corresponded to 43% of the sample. Liver transplantation was performed in 22.4% of patients of the Milan subset and in 10% of the whole sample. The overall mean survival was 60 months, with a 1-, 3- and 5-year survival probability of 74%, 40% and 29%, respectively. Lower survival was observed among patients with alcoholic etiology. Survival was higher among patients submitted to liver transplantation (P < 0.001), TACE (P < 0.001), or any kind of treatment (P < 0.001). However, no difference was found for surgical resection (P = 0.1) or sorafenib (P = 0.1). Conclusion. Patients with HCC were mainly older men diagnosed at an advanced stage. Treatment was associated with better overall survival, but few patients survived to be treated.
41
Rafael Lozano, Mohsen Naghavi, Kyle J Foreman et al. · The Lancet · 2012 · 14.3K citations · Full text
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al. · New England Journal of Medicine · 2008 · 13K citations · Full text
Medicine, Oncology, Pharmacology +12
Josep M. Llovet, Andrew K. Burroughs, Jordi Bruix · The Lancet · 2003 · 3.6K citations
AGE STANDARDIZATION OF RATES: A NEW WHO STANDARD
Omar B. Ahmad, Cynthia Boschi-Pinto, Alan D López et al. · 2000 · 1.7K citations